Table 6 All cause discontinuations
From: Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports
| Â | Â | Number (%) with outcome | Â | ||
|---|---|---|---|---|---|
Dosing (mg) | Number of trials | Sildenafil | Placebo | Relative risk (95% CI) | NNH (95% CI) |
25 | 3 | 32/312 (10) | 63/426 (15) | 0.75 (0.50 to 1.11) | Â |
50 | 5 | 36/508 (7) | 86/607 (14) | 0.52 (0.36 to 0.76) | -14 (-9 to -28) |
100 | 5 | 47/506 (9) | 86/607 (14) | 0.67 (0.47 to 0.95) | -20 (-12 to -89) |
200 | 2 | 18/191 (9) | 23/181 (13) | 0.76 (0.43 to 1.35) | Â |
Dose optimised | 5 | 52/517 (10) | 104/524 (20) | 0.50 (0.37 to 0.67) | -10 (-7 to -18) |